Comparison of Echocardiography and Myocardial Scintigraphy to Detect Cancer Therapy-Related Cardiovascular Toxicity in Breast Cancer Patients
The mortality rate of cancer patients has been decreasing; however, patients often suffer from cardiac disorders due to chemotherapy or other cancer therapies (e.g., cancer-therapy-related cardiovascular toxicity (CVR-CVT)). Therefore, the field of cardio-oncology has drawn more attention in recent...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Journal of Imaging |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2313-433X/10/3/54 |
| _version_ | 1797240494540980224 |
|---|---|
| author | Yuko Harada Kyosuke Shimada Satoshi John Harada Tomomi Sato Yukino Kubota Miyoko Yamashita |
| author_facet | Yuko Harada Kyosuke Shimada Satoshi John Harada Tomomi Sato Yukino Kubota Miyoko Yamashita |
| author_sort | Yuko Harada |
| collection | DOAJ |
| description | The mortality rate of cancer patients has been decreasing; however, patients often suffer from cardiac disorders due to chemotherapy or other cancer therapies (e.g., cancer-therapy-related cardiovascular toxicity (CVR-CVT)). Therefore, the field of cardio-oncology has drawn more attention in recent years. The first European Society of Cardiology (ESC) guidelines on cardio-oncology was established last year. Echocardiography is the gold standard for the diagnosis of CVR-CVT, but many breast cancer patients are unable to undergo echocardiography due to their surgery wounds or anatomical reasons. We performed a study to evaluate the usefulness of myocardial scintigraphy using Iodine-123 β-methyl-P-iodophenyl-pentadecanoic acid (<sup>123</sup>I-BMIPP) in comparison with echocardiography and published the results in the Journal of Imaging last year. This is the secondary analysis following our previous study. A total of 114 breast cancer patients who received chemotherapy within 3 years underwent echocardiography, as well as Thallium (<sup>201</sup>Tl) and <sup>123</sup>I-BMIPP myocardial perfusion and metabolism scintigraphy. The ratio of isotope uptake reduction was scored by Heart Risk View-S software (Nihon Medi-Physics). The scores were then compared with the echocardiography parameters. All the patients’ charts and data from January 2022 to November 2023 were reviewed for the secondary analysis. Echocardiogram parameters were obtained from 99 patients (87% of total patients). No correlations were found between the echocardiography parameters and Heart Risk View-S scores of <sup>201</sup>Tl myocardial perfusion scintigraphy, nor those of the BMIPP myocardial metabolism scintigraphy. In total, 8 patients out of 114 (7.0%) died within 22 months, while 3 patients out of 26 CVR-CVT patients (11.5%) died within 22 months. Evaluation by echocardiography was sometimes difficult to perform on breast cancer patients. However, other imaging modalities, including myocardial scintigraphy, cannot serve as alternatives to echocardiography. Cardiac scintigraphy detects circulation disorder or metabolism disorder in the myocardium; therefore, it should be able to reveal myocardial damage to some extent. The mortality rate of breast cancer patients was higher with CVR-CVT. A new modality to detect CVR-CVT besides echocardiography can possibly be anticipated for patients who cannot undergo echocardiography. |
| first_indexed | 2024-04-24T18:08:20Z |
| format | Article |
| id | doaj.art-a6d9848fe28648b692653a54d188f77c |
| institution | Directory Open Access Journal |
| issn | 2313-433X |
| language | English |
| last_indexed | 2024-04-24T18:08:20Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Imaging |
| spelling | doaj.art-a6d9848fe28648b692653a54d188f77c2024-03-27T13:48:51ZengMDPI AGJournal of Imaging2313-433X2024-02-011035410.3390/jimaging10030054Comparison of Echocardiography and Myocardial Scintigraphy to Detect Cancer Therapy-Related Cardiovascular Toxicity in Breast Cancer PatientsYuko Harada0Kyosuke Shimada1Satoshi John Harada2Tomomi Sato3Yukino Kubota4Miyoko Yamashita5Department of Cardiology, Kawasaki Municipal Ida Hospital, Kawasaki 211-0035, JapanDepartment of Breast Surgery, Kawasaki Municipal Ida Hospital, Kawasaki 211-0035, JapanSchool of Medicine, Shinanomachi Campus, Keio University, Tokyo 160-8582, JapanDepartment of Breast Surgery, Kawasaki Municipal Ida Hospital, Kawasaki 211-0035, JapanDepartment of Palliative Care Medicine, Kawasaki Municipal Ida Hospital, Kawasaki 211-0035, JapanDepartment of Radiology, Kawasaki Municipal Ida Hospital, Kawasaki 211-0035, JapanThe mortality rate of cancer patients has been decreasing; however, patients often suffer from cardiac disorders due to chemotherapy or other cancer therapies (e.g., cancer-therapy-related cardiovascular toxicity (CVR-CVT)). Therefore, the field of cardio-oncology has drawn more attention in recent years. The first European Society of Cardiology (ESC) guidelines on cardio-oncology was established last year. Echocardiography is the gold standard for the diagnosis of CVR-CVT, but many breast cancer patients are unable to undergo echocardiography due to their surgery wounds or anatomical reasons. We performed a study to evaluate the usefulness of myocardial scintigraphy using Iodine-123 β-methyl-P-iodophenyl-pentadecanoic acid (<sup>123</sup>I-BMIPP) in comparison with echocardiography and published the results in the Journal of Imaging last year. This is the secondary analysis following our previous study. A total of 114 breast cancer patients who received chemotherapy within 3 years underwent echocardiography, as well as Thallium (<sup>201</sup>Tl) and <sup>123</sup>I-BMIPP myocardial perfusion and metabolism scintigraphy. The ratio of isotope uptake reduction was scored by Heart Risk View-S software (Nihon Medi-Physics). The scores were then compared with the echocardiography parameters. All the patients’ charts and data from January 2022 to November 2023 were reviewed for the secondary analysis. Echocardiogram parameters were obtained from 99 patients (87% of total patients). No correlations were found between the echocardiography parameters and Heart Risk View-S scores of <sup>201</sup>Tl myocardial perfusion scintigraphy, nor those of the BMIPP myocardial metabolism scintigraphy. In total, 8 patients out of 114 (7.0%) died within 22 months, while 3 patients out of 26 CVR-CVT patients (11.5%) died within 22 months. Evaluation by echocardiography was sometimes difficult to perform on breast cancer patients. However, other imaging modalities, including myocardial scintigraphy, cannot serve as alternatives to echocardiography. Cardiac scintigraphy detects circulation disorder or metabolism disorder in the myocardium; therefore, it should be able to reveal myocardial damage to some extent. The mortality rate of breast cancer patients was higher with CVR-CVT. A new modality to detect CVR-CVT besides echocardiography can possibly be anticipated for patients who cannot undergo echocardiography.https://www.mdpi.com/2313-433X/10/3/54breast cancercancer-therapy-related cardiovascular toxicity (CVR-CVT)chemotherapy-related cardiac dysfunction (CTRCD)<sup>123</sup>I-BMIPPTl/BMIPP dual-isotope myocardial scintigraphy |
| spellingShingle | Yuko Harada Kyosuke Shimada Satoshi John Harada Tomomi Sato Yukino Kubota Miyoko Yamashita Comparison of Echocardiography and Myocardial Scintigraphy to Detect Cancer Therapy-Related Cardiovascular Toxicity in Breast Cancer Patients Journal of Imaging breast cancer cancer-therapy-related cardiovascular toxicity (CVR-CVT) chemotherapy-related cardiac dysfunction (CTRCD) <sup>123</sup>I-BMIPP Tl/BMIPP dual-isotope myocardial scintigraphy |
| title | Comparison of Echocardiography and Myocardial Scintigraphy to Detect Cancer Therapy-Related Cardiovascular Toxicity in Breast Cancer Patients |
| title_full | Comparison of Echocardiography and Myocardial Scintigraphy to Detect Cancer Therapy-Related Cardiovascular Toxicity in Breast Cancer Patients |
| title_fullStr | Comparison of Echocardiography and Myocardial Scintigraphy to Detect Cancer Therapy-Related Cardiovascular Toxicity in Breast Cancer Patients |
| title_full_unstemmed | Comparison of Echocardiography and Myocardial Scintigraphy to Detect Cancer Therapy-Related Cardiovascular Toxicity in Breast Cancer Patients |
| title_short | Comparison of Echocardiography and Myocardial Scintigraphy to Detect Cancer Therapy-Related Cardiovascular Toxicity in Breast Cancer Patients |
| title_sort | comparison of echocardiography and myocardial scintigraphy to detect cancer therapy related cardiovascular toxicity in breast cancer patients |
| topic | breast cancer cancer-therapy-related cardiovascular toxicity (CVR-CVT) chemotherapy-related cardiac dysfunction (CTRCD) <sup>123</sup>I-BMIPP Tl/BMIPP dual-isotope myocardial scintigraphy |
| url | https://www.mdpi.com/2313-433X/10/3/54 |
| work_keys_str_mv | AT yukoharada comparisonofechocardiographyandmyocardialscintigraphytodetectcancertherapyrelatedcardiovasculartoxicityinbreastcancerpatients AT kyosukeshimada comparisonofechocardiographyandmyocardialscintigraphytodetectcancertherapyrelatedcardiovasculartoxicityinbreastcancerpatients AT satoshijohnharada comparisonofechocardiographyandmyocardialscintigraphytodetectcancertherapyrelatedcardiovasculartoxicityinbreastcancerpatients AT tomomisato comparisonofechocardiographyandmyocardialscintigraphytodetectcancertherapyrelatedcardiovasculartoxicityinbreastcancerpatients AT yukinokubota comparisonofechocardiographyandmyocardialscintigraphytodetectcancertherapyrelatedcardiovasculartoxicityinbreastcancerpatients AT miyokoyamashita comparisonofechocardiographyandmyocardialscintigraphytodetectcancertherapyrelatedcardiovasculartoxicityinbreastcancerpatients |